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ACKGROUND: Low-HDL cholesterol is a 
risk factor of CAD. Although levels of HDL-
C are within normal limit in some patients, 
they suffer CAD. These normal HDL-C levels might 
become pro-inﬂammatoric. This study is to measure 
the correlations between myeloperoxidase (MPO), 
serum amyloid-A (SAA) protein, and secretory-
phospholipase-A2 (sPLA2) with inﬂammatory status 
of HDL-C.
METHODS: This was a cross-sectional study 
recruited 49 subjects with high HDL-C (> 40 mg/
dL) and 31 subjects with low HDL-C (< 40 mg/dL). 
HDL-C was determined into antiinﬂammatory and 
proinﬂammatory based on levels of Apo A-1 and 
hs-CRP. Concentrations of MPO, SAA and s-PLA2 
were measured by ELISA method. Levels of Apo A-
1 was determined by immunoturbidimetric method. 
Multiple logistic regression analysis was done using 
inﬂammatory status of HDL-C as dependent variables 
and levels of MPO, SAA, sPLA2, ages, total cholesterol 
and triglycerides as independent variables.
RESULTS: Patient’s age was 43.4 + 8.3 year, HDL-C 
was 43.1 + 9.5 mg/dL, Apo A-1 was 128.3 + 21.5 mg/
dL, hs-CRP was 1.92 + 3.0 mg/dL. Concentrations of 
MPO, SAA and sPLA2 successively were 63.2 + 16.9 
ng/mL, 7015.6 + 5021.1 ng/mL and 1340.2 + 406.3 pg/
mL. Multiple logistic regression analysis showed that 
SAA is an independent predictor of pro-inﬂammatory 
status of HDL-C in high HDL-C group with prevalence 
ratio of 11.74 (95% CI : 2.51 – 54.84; P = 0.002). In contrast, 
MPO and sPLA2 were not independent predictor with 
PR of  1.26 (95% CI : 0.30 – 5.23; P = 0.75) and of 0.94 
(95% CI : 0.23 – 3.91; P = 0.93).
CONCLUSIONS:  SAA is an independent predictor 
of pro-inﬂammatory HDL-C even in subjects with 
high HDL-C.
KEYWORDS: Atherosclerosis, Apo A-I, serum 
amyloid A protein, secretory phospholipase A2, 
myeloperoxidase
Not all HDL (High Density Lipoprotein) protect 
against plaque formation in the arterial walls. This 
is because in some people HDL was dysfunction, or 
malformed, and unable to do its job properly. The 
fact that sometimes HDL doesn’t do its job properly 
can explain why some people who have high HDL 
levels still get heart attacks and suffer from other 
cardiovascular disease.
Some researchers found that HDL becomes 
dysfunction when an enzyme from white blood cells, 
called myeloperoxidase (MPO), binds to Apo A-1 and 
modiﬁes it. Once modiﬁed, Apo A-1 blocks HDL’s 
ability to perform its normal physiological function.
Figure 1. Converting the HDL from anti-inﬂammatory to 
proinﬂammatory (Adapted from Fogelman AM, 2004)
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SAA (Serum Amyloid A) is transported in the 
circulation primarily in association with HDL. SAA 
levels increase rapidly in the blood of humans suffering 
from acute and chronic inﬂammation. SAA has been 
proved can replace Apo A-1 in HDL in vitro. Because 
SAA binds to proteoglycans, SAA-containing HDL 
could bind to extracellular vascular proteoglycans, 
which would favor the retention and modiﬁcation of 
HDL by the vascular matrix. Retention could prevent 
HDL from participating in the reverse cholesterol 
transport and inhibiting oxidative processes in the 
arterial wall. Modiﬁcations of lipid and protein 
components of trapped HDL might increase its 
interactions with macrophage scavenger receptors.
Figure 2. During the acute-phase reaction the protein and lipid 
composition of the HDL changes rapidly (Adapted from Rohrer, 
2004)
sPLA2 (secretory Phospholipase A2)  also had a 
role as atherosclerotic marker and mediator in human. 
Like SAA, it also can be bound to HDL.
High level of MPO, SAA and sPLA2 can change 
HDL characteristics from antiinﬂammatory to 
proinﬂammatory, which means can change  HDL 
quality. If so, HDL quality actually become more 
important than HDL quantity.
It might also be that the strategy of increasing 
HDL levels per se is not enough, and some researchers 
believe that it is the function oh HDL that needs to be 
improved rather than its levels (1).
 stnetnoc dipil sti yb denimreted eb nac ytilauq LDH
(including oxidized lipid) and apolipoprotein in HDL, 
particle size and electrophoretic mobility, related 
enzymatic activity, inﬂammatory/antiinﬂammatory 
properties and ability to promote cholesterol efﬂux 
(2).
A few studies to date have investigated the 
correlation between SAA, sPLA2 and MPO with the 
change of HDL characteristics from antiinﬂammatory 
to proinﬂammatory. According to that reason, we need 
to study about the correlation between SAA, sPLA2 
and MPO with proatherogenic HDL. Proinﬂammatory 
HDL term was used when one of the atheroprotective 
HDL characteristics was disturbed. Proinﬂammatory 
HDL were determined by ApoA-I and hsCRP 
concentration.
Patients and Methods
Forty nine (49) healthy male person with high 
Cholesterol-HDL ( > 40 mg/dL), aged 33–62 years 
(man) were enrolled in this cross sectional study. 
Thirty one (31) healthy male person with low 
Cholesterol-HDL (< 40 mg/dL)  aged 30–59 years 
also were analysed. Participants signed informed 
consents to have personal data such as height, weight, 
smoking, serum measurements, blood pressure, waist 
circumference, exercises, alcohol, drugs.
  
Assays of  Biochemical  Markers
Serum Amyloid A (SAA) Protein, secretory 
Phospholipase A2 (sPLA2) and MPO concentrations 
were measured with Enzyme Linked Immuno 
Assay kit from Anogen, Cayman, and Calbiochem 
respectively. Serum were separated from whole blood 
after centrifugation, and immediately kept at –20oC 
until assays. All assays were performed according to 
manufacturers instruction.
For each run of SAA Protein, sPLA2 and MPO, 
controls were included in the assays, and all results 
were within acceptable ranges. In our laboratory, the 
intraday imprecisions for all assays were between 
4.2% - 5.4%.
-  Statistical analyses were performed with the 
SPSS for Windows version 13.0 software. Uni-
variate, bivariate and multivariate analysis were 
calculated. The results were narrated and ex-
plained by tables and graphics.
- For statistical test, we used 5% signiﬁcance.
Statist ical  Analysis
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Patient’s age was 43.4 + 8.3 year, HDL-C was 43.1 + 9.5 mg/dL, Apo A-1 was 128.3 + 21.5 mg/dL, hs-CRP was 
1.92 + 3.0 mg/dL. Concentrations of MPO, SAA and sPLA2 successively were 63.2 + 16.9 ng/mL, 7015.6 + 5021.1 
ng/mL and 1340.2 + 406.3 pg/mL.
Table 1. Median levels of Apo A-1, SAA, sPLA2, MPO and hs-CRP
Apo A-1
(mg/dL)
SAA
(ng/mL)
sPLA2
(pg/mL)
MPO
(ng/mL)
hs-CRP
(mg/L)
N8 08 07 97 98 0
Median 125,00
(90-201)
5905,00
(423,2-20.410,0)
1316,00
(293-2565)
62,30
(32,7-101,8)
1,10
(0,1-22,4)
SAA = Serum Amyloid A; sPLA2 = secretory Phospholipase A2; MPO = Myeloperoxidase; hs-CRP = high sensitivity C-Reactive Protein
HDL-C was deﬁned as proinﬂammatory based on levels Apo A-1 < 125 mg/dL, and or hs-CRP > 1,1 mg/L. From 
49 subjects with high HDL-C (> 40 mg/dL), by using that criteria we found 28 subjects with antiinﬂammatory 
properties and 21 subjects with proinﬂammatory properties. S tatistical analysis was made using independent 
sample t test to see the different between SAA, sPLA2 and MPO.
Table 2. Level of Apo A-1, SAA, sPLA2, MPO and hs-CRP among  HDL type (antiinﬂammatory/
proinﬂammatory) in high HDL-C group
HDL type N Mean + SD P
Apo A-1    Antiinﬂammatory
                 Proinﬂamamatory
28
21
144,61 + 20,83
132,09 + 15,26
0,025
SAA          Antiinﬂammatory
                 Proinﬂamamatory 
28
21
5303,42 + 3967,15
10903,86 + 4546,75
0,000
sPLA2      Antiinﬂammatory
                 Proinﬂamamatory
28
21
1216,21 + 386,14
1453,38 + 391,55
0,040
MPO         Antiinﬂammatory
                 Proinﬂamamatory
28
21
60,20 + 16,80
61,26 + 18,03
0,833
hs-CRP    Antiinﬂammatory
                 Proinﬂamamatory
28
21
0,64 + 0,31
3,74 + 5,20
0,003
HDL = High Density Lipoprotein; SAA = Serum Amyloid A; sPLA2 = secretory Phospholipase A2; MPO = Myeloperoxidase; hs-CRP = high 
sensitivity C-Reactive Protein
Result s
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Tabel 3. Multiple logistic regresion analysis
Variabel B Wald p Prevalence ratio (95% CI)
SAA
sPLA2
MPO
age
total chol.
tryglyceride
Constanta
2,463
-0,061
0,235
-0,060
-0,009
0,007
1,455
9,816
0,007
0,104
1,689
0,285
1,134
0,175
0,002
0,933
0,747
0,194
0,594
0,287
0,676
11,744
0,940
1,265
0,942
0,992
1,007
4,285
(2,515 – 54,839)
(0,226 – 3,912)
(0,304 – 5,272)
(0,861 – 1,031)
(0,961 – 1,023)
(0,994 – 1,020)
-
SAA = Serum Amyloid A; sPLA2 = secretory Phospholipase A2; MPO = Myeloperoxidase
Multiple logistic regression analysis showed that SAA is an independent predictor of pro-inﬂammatory status of 
HDL-C in high HDL-C group with prevalence ratio of 11.74 (95% CI : 2.51 – 54.84; P = 0.002). In contrast, MPO 
and sPLA2 were not independent predictor with PR of  1.26 (95% CI : 0.30 – 5.23; P = 0.75) and of 0.94 (95% CI : 
0.23 – 3.91; P = 0.93).
 
Discussions
Normally, HDL exert a range of potent biological 
activities that provide protection against 
atherosclerosis. These actions include a key role 
in mediating cholesterol efﬂux from plaque 
macrophages and foam cells, and from peripheral 
tissues, with transport to the liver for excretion 
via the process of reverse cholesterol transport; 
equally, anti-oxidant, anti-inﬂammatory, anti-
apoptotic, anti-thrombotic, anti-infectious and 
vasodilatory properties are central features of HDL-
mediated atheroprotection. HDL particles are highly 
heterogeneous in terms of their physico-chemical 
characteristics, structure, intravascular metabolism 
and biological activity.
The role of HDL in atherosclerosis is not 
apart from the role of  Apo A-1. Apo A-1 ability to 
promote reverse cholesterol transport and remove 
seeding molecule from LDL (important in oxidized 
phospholipids formation, originate  from LDL 
inﬂammatory) contribute to inverse relationship 
between HDL-cholesterol level and susceptibility to 
atherosclerosis (3).
HDL can bind and neutralize lipopolysaccharide, 
to modulate acute and chronic inﬂammation. 
Flowcytometry analysis shows that Apo A-1 associated 
with HDL can inhibit monocyte activation by binding 
to T lymphocyte, to inhibit tumor necrosis factor (TNF)-
 and interleukin-1  production, essential component 
on immunoinﬂammatory diseases pathogenesis. It has 
been hypothesised that increasing HDL have an effect 
on  antiinﬂammation action (5).
 In this study,  subject were divided into high HDL 
group  (HDL >  40 mg/dL, n = 49) and low HDL group 
(HDL < 40 mg/dL, n = 31). Based on median of Apo A-
1 (125 mg/dL) and hs-CRP (1,1 mg/L) we determined 
HDL antiinﬂammatory type if the subject has Apo 
A-1 > 125 mg/dL and/or has hs-CRP < 1,1 mg/L, 
and HDL proinﬂammatory if the subject  has Apo A-
1 < 125 mg/dL and/or has hs-CRP > 1,1 mg/L. From 
49 subjects with high HDL  we found 28 subject with 
HDL antiinﬂammatory type and 21 subjects with HDL 
proinﬂammatory. From subjects with low HDL we found 
only 1 subject with HDL anti-inﬂammatory type and  30 
subjects with HDL proinﬂammatory type. 
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Table 4. The type of HDL in high HDL and low HDL  groups
HDL group HDL antiinﬂammatory HDL proinﬂammatory Total
HDL > 40 mg/dL 28 21 49
HDL < 40 mg/dL 1 30 31
Total 29 51 80
 
HDL = High Density Lipoprotein
In our study from 49 subjects with HDL > 40 
mg/dL there are 21 subjects  (42,86%) who have 
HDL proinﬂammatory type and 28  subjects (57,14%) 
having HDL anti-inﬂammatory type. It means that 
in high HDL group, we found subject with HDL 
proinﬂammatory type. So, if we just only think about 
quantity of  HDL, we cannot assured of  its quality. 
On the other hand, we found in low HDL group 30 
subjects with HDL proinﬂammatory type  (96,77%). 
From the whole population study  (n = 80), 51 
subjects (63,75%) have HDL proinﬂammatory type 
and  29 subjects (36,25%) have HDL anti-inﬂammatory 
type.
From high HDL group, that we were focusing 
 AAS hgih htiw stcejbus 82 dnuof ew ,yduts siht no
(57,14%), 25 subjects with high  sPLA2 (51,02%) 
and 22 subjects with high MPO (44,90%). Possibly 
because there is big relationship with the ﬁnding of 
HDL proinﬂammatory in high HDL group. In some 
subjects with high HDL level (formerly thought to be 
protective) when accompanied by high MPO, and/or 
high  SAA, and/or high sPLA2, the HDL function will 
be disturbed, that shown by low Apo A-1 and/or high 
hs-CRP. 
From our study we found :
- there was signiﬁcant positive correlation between 
SAA with  HDL proinﬂammatory, with  prevalence 
ratio  10,800, p = 0,001.
- there was weak positive correlation between 
sPLA2 with HDL proinﬂammatory, prevalence 
ratio 1,100, p = 0,869.
- there was  weak positive correlation between MPO 
 oitar ecnelaverp htiw yrotammaﬂniorp LDH htiw
0,865, p = 0,804.
- SAA is the best independent predictor by 
multivariate logistic regression analysis wit  h
prevalence ratio 11,744 ; p = 0,002, followed by 
MPO and sPLA2.
1. Interaction between SAA, sPLA2 and MPO in
HDL proinlammatory
Several epidemiological studies showed inverse 
relationship between HDL and artery coroner disease risk. 
Part of HDL protective effect is caused by LDL oxidative 
modiication inhibition or by promoting cholesterol 
eflux from pheriferal cells. In certain condition, eg. 
acute phase reactant, native antioxidant properties of 
HDL were changed. Just the opposite from native HDL 
that inhibit LDL modiication and monocyte adhesion to 
endothelial cells in artery cocultur system, acute phase-
HDL will increase monocyte adhesion. In acute phase, 
lipoprotein composition change dramatically from non 
acute phase condition. In this condition, HDL showed big 
increasing SAA, with decreasing Apo A-1 level. HDL-
containing Apo A-1 particle consist of lecithin cholesteryl 
acyl transferase (LCAT), that responsible for plasma 
cholesterol esteriication and acting as HDL ligand that 
has role in HDL interaction with cell. Apo A-1 substitution 
by SAA within acute phase can inhibit LCAT activity in 
HDL, repressing cholesterol eflux from pheriferal cells 
(6).
 Recent study has evaluated HDL protective effect. 
HDL-enriched with SAA does not have protective effect. 
This study suggested that within acute phase, joining 
SAA into HDL can cause changing in HDL particle, and 
diminished protective capacity to LDL oxidation. Acute 
phase-HDL is not only inhibit LDL oxidation but also 
result in monocyte migration (6). 
 In our study, we found 28 person (57,14%) who 
has high level of SAA in high HDL group. By using 
univariate logistic regression analysis we found that 
in high HDL group, SAA is the best independent 
predictor with prevalence ratio 10,800 (95% CI : 
2,543 – 45,866), p : 0,001, on the other hand based on 
multivariate regression analysis shown that in high 
HDL group SAA is still best independent predictor
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with prevalence ratio 11,744 (95% CI : 2,515 – 54,839) 
p : 0,002, followed by MPO and sPLA2 respectively. It 
means that serum SAA level is signiicantly associated 
and independent with proinlammatory HDL type.
 This result similar with van Lenten inding. They 
found decreasing 73% Apo A-1 level in people with high 
SAA level. People with high level of HDL, if accompanied 
by high SAA can have proinlammatory HDL type.
 Secretory Phospholipase A2 (sPLA2) is an enzyme 
that break acyl ester in sn-2 position in glycerophospholipid 
when activated. sPLA2 is extracellular enzyme with 
high disulphide binding, with low molecular weight (14 
KDa), and need mM Ca2+ for catalysis. This enzyme has 
important role in arachidonic and eicosanoid formation, 
proinlammatory mediator. PLA2 has several biological 
action such as immunologic respons, inlammation, cellular 
proliferation, vasoconstriction and bronchioconstriction.
 Circulating sPLA2 level will increase dramatically 
within infection and inlammation. In nonatherosclerotic 
artery, sPLA2 type IIA especially associated with smooth 
muscle cells. In atherosclerotic lesion, this enzyme 
associated with macrophage, necrotic lipid core and 
extracellular vascular proteoglican. This enzyme was 
bound with very high afinity (7).
 Our study found 25 person (51%) who has high 
sPLA2 in high HDL group. Based on univariate logistic 
regression analysis sPLA2 was not proven associated 
signiicantly with proinlammatory HDL type. This is not 
similar with former reports that mention that in person 
with high HDL level, if accompany by high sPLA2, his 
HDL will change to proinlammatory type.
 There are several possibilities as a cause for these 
differences. First, there are some steps in the testing 
procedure that should be paid attention. The higher 
standard to achieve standard curve is 1.000 pg/mL, and 
our results are in the range 293 to 2.696 pg/mL. Mean 
+ SD : 1340,18 + 406,27 pg/mL. Diluting factor is very 
important if we want to continue this research. Second, 
absorbance reading also can be done several times (15, 
30, 60, 120, 240, 360 minutes). In our research, we used 
value only at 15 and 30 minutes reading, and we calculate 
the difference. Perhaps, this reading method inluence the 
value. Third, we used sPLA2 (human Type IIa) EIA kit 
that measure sPLA2 concentration.
Maybe it will be better to use kit that measure sPLA2 activity, 
because measurement of enzyme activity generally has better 
correlation than measuring the concentration. Fourth, the 
number of research sample too small so it is not enough to 
prove the double hypothesis in this research. Fifth, the recent 
researchs usually predict the correlation between high sPLA2 
with proinlammatory properties of low HDL. We want to 
know wheter the inluence of this high sPLA2 can happen 
in high HDL group with proinlammatory properties. Our 
analysis shown that sPLA2 mean in high HDL group with 
proinlammatory properties higher than sPLA2 mean in low 
HDL group. Possibly sPLA2 can inluence to change HDL 
properties, from anti-inlammatory to proinlammatory, but 
this effect need long time to occur.
 Modiication by MPO product, can cause Apo A-1 bind 
tightly to the artery. Similarly with the inding in Fogelman 
study that in atherosclerosis artery, we can ind Apo A-1 in a 
big amount. In a non modiied-Apo A-1, on the contrary, the 
normal Apo A-1 doesn’t have binding site with heparin. So 
we can ind more Apo A-1 in plasma than in artery (8). Level 
of hs-CRP > 3 mg/L will strengthen the prediction about 
inlammation and showing the risk to get cardiovascular 
disturbances in the future if doesn’t treat earlier. 
 Even oxidation product by MPO can be found more 
abundant in circulation HDL in individu with CVD and 
atherosclerosis lesion, in fact signiicant amount also can be 
found in Apo A-1 from the healthy individual serum (9).
 We found 22 individu (44,9%) with high MPO in high 
HDL group. Based on univariate logistic regression analysis, 
the prevalence ratio is 0,865 (95% CI : 0,277 – 2,705) with 
p = 0,804. With multivariate logistic regression analysis, the 
prevalence ratio is 1,265 (95% CI: 0,304 – 5,272) with p = 
0,747. It means that MPO doesn’t have signiicant association 
with proinlammatory-HDL. It is different with the previous 
studies which show that in individu with high HDL 
accompany by high MPO, the HDL become proinlammatory 
HDL.
 There are some possibilities as the cause of this 
differences. First, Apo A-1 oxidation catalyzed by 
MPO in arterial wall or in circulation, not followed by 
selective deposition of modiied lipoprotein in arterial 
wall, so Apo A-1 still can be measured in the blood. 
Besides, we must remember that – different from LDL 
that has only one Apo B on its each particle- more than 
one Apo A-1 can be found on each HDL particle. This
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deposition issue was still a question mark for previous 
researchers and has not yet been answered by existing 
studies. Factors that inﬂuence the modiﬁed Apo A-
1 deposition in the artery wall have to be found out. 
Second, the process of Apo A-1 modiﬁcation progress 
slowly that it takes quite a long time to be able to alter 
the HDL function to become pro-inﬂammatory. Other 
studies using the case control or cohort designs are 
probably needed. Subjects with elevated MPO can 
be reexamined at another time for the HDL type, to 
see if there is any change to pro-inﬂammatory HDL. 
Third, to get a better understanding about the pro-
inﬂammatory HDL, we indeed need to measure 
not only the Apo A-1 concentration, but also the 3-
chlorotyrosine in HDL using mass spectrophotometry. 
Increased 3-chlorotyrosine in HDL indicated high level 
of Apo A-1 modiﬁcation by MPO (10).
2. Relationship between Study Results and 
Epidemiological Data
Recently, several reports had given a number of 
data supporting the statement of the involvement 
of MPO in HDL pro-inﬂammatory characteristics. 
This is suggested to associate with the MPO ability 
(through its products) to modify Apo A-1. When Apo 
A-1 is modiﬁed by MPO, it will block the normal HDL 
function. There is an inverse relationship between 
the amount of tyrosine in apoA-I modiﬁed by MPO-
derived products and the ability of HDL to remove 
cholesterol from macrophages. Thus, the more tyrosine 
in apoA-I that is modiﬁed by MPO-derived products, 
the less effective the HDL is in removing cholesterol. 
Modiﬁed Apo A-1 will tightly bind the artery wall, 
unlike the unmodiﬁed Apo A-1. Our study revealed 
different thing. In group with HDL ≥ 40 mg/dL, we 
found weak correlation between MPO activity with the 
Apo A-1 concentration in blood (r = 0.250; p = 0.083). 
Besides, MPO activity also had very weak correlation 
with hs-CRP (r = 0.140; p = 0.315), and unsurprisingly, 
the univariate or multivariate regression analysis of 
MPO did not show signiﬁcant association with HDL 
type. MPO is not a strong indicator for the change of 
HDL characteristics from anti-inﬂammatory to pro-
inﬂammatory. From this study, we found that SAA 
concentration in group with HDL ≥ 40 mg/dL had 
weak correlation with Apo A-1 concentration in blood 
(r = 0.261; p = 0.070), but had strong correlation with hs-
CRP (r = 0,453*; p = 0.005). Based on previous reports 
by other researchers, the decrease in plasma Apo A-1 
levels with induction of the acute phase response has 
been attributed to displacement of Apo A-1 from HDL 
particle with SAA in vivo and in in vitro (11). The real 
mechanism of the displacement of Apo A-1 with SAA, 
has not been known until now.
This study also showed that in the group with HDL 
≥ 40 mg/dL, the concentration of sPLA2 correlated 
weakly with the concentration of Apo A-1 in blood 
samples (r= -0.303*; p = 0.034). In the meantime, the 
concentration of sPLA2 had strong correlation with 
increased hs-CRP (r=0.503*; p=0.000). This ﬁnding 
was probably because we measured the concentration 
of the enzymes of sPLA2, and not directly the sPLA2 
activity, and high concentration may not always mean 
high activity. The activity of sPLA2 in hydrolyzing 
phospholipids can release oxidized fatty acid from 
lipoprotein including HDL, which is pro-inﬂammatory 
and pro-atherogenic. The research by Rohrer showed 
a high concentration of CRP in elevated sPLA2 (12).
Relationship between HDL level and cardio-
vascular disease has been widely known. Low HDL 
level is related to high risk of CVD. In our study, 
44.9% of individual with elevated HDL (considered 
protective) found to have high MPO, 51% had high 
sPLA2 and 57.14% had high SAA. On the whole, 
87.8% of individual with elevated HDL level had high 
MPO and/or high sPLA2 and/or high SAA. Looking 
at the result of this study, it is appropriate if these 
markers are also observed at the time of performing 
other cardiovascular risk factors tests. The next thing 
is the estimation of the effect of MPO, sPLA2 and SAA 
on HDL function.
Association between SAA, sPLA2, MPO and the 
forming of pro-inﬂammatory HDL is very likely to 
be inﬂuenced by factor of time, how long the HDL is 
exposed with those three factors. In our study, SAA 
factor had better correlation with HDL than sPLA2 
and MPO.
3. Cause-Effect Relationship in Study Variables
Interaction between the concentration of MPO, sPLA2 
and SAA with pro-inﬂammatory HDL indicated that 
SAA was involved in HDL characteristics change from 
anti-inﬂammatory to pro-inﬂammatory, which was 
indicated with Apo A-1 level < 125 mg/dL and/or 
hs-CRP > 1.1 mg/L. This is suggested to be related to 
increasing in atherosclerosis risk. Thus, when early 
intervention can be done either by life style modiﬁcation 
or therapeutic treatment which is intended to reduce 
this risk, the change of HDL characteristics from anti-
inﬂammatory to pro-inﬂammatory can indeed be 
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inhibited and it can decrease the incidence of CVD 
in the future.
The exact mechanism of interaction among MPO, 
sPLA2 and SAA has not been known for certain.
The question need to be answered is how life 
style modiﬁcation or early therapeutic treatment 
can reduce/decrease atherosclerosis progression? 
Related to that, our study result about SAA is 
expected not just to be able to estimate the change of 
HDL characteristics from anti-inﬂammatory to pro-
inﬂammatory, but also to give additional information 
regarding the incidence of CVD. Therefore SAA 
determination, besides lipid proﬁle and other risk 
factors of CVD, shows a promising future.
4. Analysis of the Interaction of Variables in 
the Incidence of HDL Characteristics Change 
from anti-inflammatory to pro-inflammatory by 
pathobiological approach
In analysing the incidence of HDL characteristics 
change from anti-inﬂammatory to pro-
inﬂammatory, the core hypothesis approach of 
oxidative stress-inﬂammation-atherosclerosis is a 
powerful pathobiological mechanistic approach. 
The epidemiological and clinical facts provided 
convincing data about incidence of cardiovascular 
disease in individuals with normal HDL. In this study, 
we tried to observe the interaction of each variable 
in pathobiological concept in the incidence of HDL 
characteristics change from anti-inﬂammatory to 
pro-inﬂammatory.
In condition exposed with MPO, sPLA2 and 
SAA for a long time, HDL with anti-inﬂammatory 
characteristics undergo dysfunction and become pro-
inﬂammatory. Pro-inﬂammatory characteristics of 
HDL are indicated by low Apo A-1 and/or elevated 
hs-CRP. 
Our study resulted in a cut off value for SAA in 
HDL characteristics change from anti-inﬂammatory 
to pro-inﬂammatory. However, our study result was 
still unable to give explanation of how the mechanism 
of the anti-inﬂammatory HDL characteristics 
changed to anti-inﬂammatory, from a “good” micro-
environment to a bad one. To explain the phenomena 
about the importance of “quality” besides “quantity”, 
further deeper studies would be needed.
1. SAA concentration is independent and signiﬁcantly 
associated with proinﬂammatory HDL type in 
healthy subjects.
2. sPLA2 concentration is not associated with 
proinﬂammatory HDL type in healthy subjects.
3. MPO concentration is not associated with 
proinﬂammatory HDL type in healthy subjects.
4. Interaction model among SAA, sPLA2 and MPO, 
showed that SAA has the best association with 
proinﬂammatory HDL type.
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